Latest Breaking News On - Nivolumab plus talazoparib - Page 1 : vimarsana.com

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.

United statesJames isaacsDepartment of hematologyMedical oncologyCleveland clinicCleveland clinic gross family melanoma registryNivolumab plus talazoparibAacr annual meeting